- Home
- ICCM vs FBIO Comparison
ICCM vs FBIO Comparison
Compare ICCM & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- FBIO
- Stock Information
- Founded
- ICCM 2006
- FBIO 2006
- Country
- ICCM Israel
- FBIO United States
- Employees
- ICCM N/A
- FBIO N/A
- Industry
- ICCM
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- FBIO Health Care
- Exchange
- ICCM Nasdaq
- FBIO Nasdaq
- Market Cap
- ICCM 61.1M
- FBIO 88.7M
- IPO Year
- ICCM N/A
- FBIO N/A
- Fundamental
- Price
- ICCM $1.06
- FBIO $2.84
- Analyst Decision
- ICCM Strong Buy
- FBIO Strong Buy
- Analyst Count
- ICCM 1
- FBIO 2
- Target Price
- ICCM $2.00
- FBIO $16.50
- AVG Volume (30 Days)
- ICCM 1.9M
- FBIO 648.5K
- Earning Date
- ICCM 08-13-2025
- FBIO 08-14-2025
- Dividend Yield
- ICCM N/A
- FBIO N/A
- EPS Growth
- ICCM N/A
- FBIO N/A
- EPS
- ICCM N/A
- FBIO N/A
- Revenue
- ICCM $2,787,000.00
- FBIO $59,301,000.00
- Revenue This Year
- ICCM $62.11
- FBIO $51.59
- Revenue Next Year
- ICCM $142.91
- FBIO $44.74
- P/E Ratio
- ICCM N/A
- FBIO N/A
- Revenue Growth
- ICCM N/A
- FBIO N/A
- 52 Week Low
- ICCM $0.48
- FBIO $1.33
- 52 Week High
- ICCM $1.66
- FBIO $3.08
- Technical
- Relative Strength Index (RSI)
- ICCM 57.34
- FBIO 73.06
- Support Level
- ICCM $1.01
- FBIO $2.30
- Resistance Level
- ICCM $1.12
- FBIO $3.08
- Average True Range (ATR)
- ICCM 0.07
- FBIO 0.20
- MACD
- ICCM 0.02
- FBIO 0.08
- Stochastic Oscillator
- ICCM 47.92
- FBIO 78.38
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.